Blueprints for agents activating immune responses (vaccines) are needed. The principles have been elusive because many immune system receptors (e.g., the lectin DC-SIGN) can transmit signals that lead to either immunity or tolerance. We are developing tools to elucidate the combination of signals required to elicit anti-cancer immunity. To this end, we found that glycan conjugates that target DC-SIGN give rise to potent signals that result in anti-cancer immunity. This seminar will discuss the relevant design features of these conjugates and the mechanisms underlying their activity against tumors.

Co-opting immunity with multivalent conjugates

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.